Novavax (NVAX) Given Daily Media Sentiment Score of 0.20

Marco Green
March 4, 2018

The company's stock had a trading volume of 18,030,361 shares, compared to its average volume of 14,500,000. Although the biotech's stock has cooled off in the interim, Novavax's shares are still up by a healthy 7% as of 2:44 p.m. EST.

Currently, the 14-day Relative Strength Index (RSI) reading is at 63.22. The RSI oscillates between zero and 100. The objective of using RSI is to help the trader identify over sold and overbought price areas.

Wall Street brokerages forecast that Novavax, Inc. (NVAX) is at 54.68. Piper Jaffray Companies' price target indicates a potential upside of 15.21% from the company's previous close. The shares now trade at $28.00 and have been able to report a change of -12.47% over the past one week. This is the price at which the trader or investor wants to exit his existing position so he can realize the most reward. There is no concrete way to calculate a price target. In last 4 months performance of NNI was 6.14% while its price to sale ratio is 1.81 and price to book ratio is 1.09. Citigroup upgraded Novavax from a "neutral" rating to a "buy" rating and set a $2.00 target price for the company in a research report on Tuesday, October 31st. A hold position is not a bad one, and even stocks that are denoted as a hold can appreciate in price over time. (NASDAQ:NVAX) for 11,916 shares. According to their predictions high & low revenue estimates are 10.3 Million and 6 Million respectively. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company's stock worth $103,000 after acquiring an additional 29,800 shares during the period. For the next fiscal year, analysts expect that the company will post sales of $32.82 million per share, with estimates ranging from $27.50 million to $39.60 million.

Novavax, Inc. institutional ownership is held at 42.2% while insider ownership was 0.1%. Novavax earned a news impact score of 0.12 on Accern's scale. Canada Pension Plan Investment Board now owns 567,800 shares of the biopharmaceutical company's stock worth $647,000 after buying an additional 92,900 shares in the last quarter.

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise.

Novavax, Inc. (NASDAQ:NVAX)'s stock on Wednesday traded at beginning with a price of $2.25 and when day-trade ended the stock finally slumped -3.56% to reach at $2.17. Average estimation for the current quarter has been provided by 8 analysts.

The company's Market capitalization is $755.92M with the total Outstanding Shares of 321.67M. While 20-Day Moving Average VS Current Price shows "Buy" Signal. This battle between buyers and sellers for the best price in all different time frames creates movement while longer-term technical and fundamental factors play out.

Traders will often use multiple moving averages to analyze a single security.

A moving average can help cut down the amount of "noise" on a price chart. Novavax, Inc. (NVAX) recently closed with rise of 10.43% to its 20-Day Simple Moving Average. The Weekly and Monthly Volatility stands at 7.02% and 7.41%. Schwab Charles Investment Management Inc. now owns 1,225,018 shares of the biopharmaceutical company's stock worth $1,397,000 after buying an additional 71,047 shares in the last quarter. Keep in mind that Investors should not rely only on an analyst's recommendation when taking a decision whether to buy, hold, or sell a stock.

Analyst notified mean rating at 2.60 after consensus analysis. SELL rating has been given by 1 analyst (s) and 4 analyst (s) given BUY rating to the stock.

Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance. The Stock has its 52-week High of $2.60 and 52-Week Low of $0.73 and it touched its 52-week high on 02/20/18 and 52-Week Low on 05/08/17.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER